Status:
COMPLETED
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: * The characteristics and treatment sequence of patients treated with nivolumab * The effe...
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Pathologically confirmed diagnosis of advanced NSCLC
- Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label
- Previously treated with at least one prior chemotherapy- containing regimen
Exclusion
- Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs
- Participants with a diagnosis of another primary cancer within the past five years
- Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
September 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 18 2025
Estimated Enrollment :
535 Patients enrolled
Trial Details
Trial ID
NCT04500535
Start Date
September 28 2020
End Date
April 18 2025
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Paris, France, 75248